(UroToday.com) Up to 30% of metastatic castration-resistant prostate cancer (mCRPC) men harbor DNA damage repair defects and may benefit from poly-ADP ribose polymerase (PARP) inhibitors after abiraterone/enzalutamide and docetaxel failure. Cabazitaxel was recently shown to improve overall survival in this population,1 though benefit by DNA damage repair status is unknown. At the prostate cancer session during the European Society of Medical Oncology – 2020 Virtual Congress (ESMO), Dr. Mihaela Aldea and colleagues reported outcomes of their assessment of cabazitaxel activity in men with mCRPC according to their DNA damage repair status.